| Literature DB >> 25824707 |
Karin Ortmayr1, Stephan Hann, Gunda Koellensperger.
Abstract
Efficient and robust separation methods are indispensable in modern LC-MS based metabolomics, where high-resolution mass spectrometers are challenged by isomeric and isobaric metabolites. The optimization of chromatographic separation hence remains an invaluable tool in the comprehensive analysis of the chemically diverse intracellular metabolome. While it is widely accepted that a single method with comprehensive metabolome coverage does not exist, the potential of combining different chromatographic selectivities in two-dimensional liquid chromatography is underestimated in the field. Here, we introduce a novel separation system combining reversed-phase and porous graphitized carbon liquid chromatography in a heart-cut on-line two-dimensional setup for mass spectrometry. The proposed experimental setup can be readily implemented using standard HPLC equipment with only one additional HPLC pump and a two-position six-port valve. The method proved to be robust with excellent retention time stability (average 0.4%) even in the presence of biological matrix. Testing the presented approach on a test mixture of 82 relevant intracellular metabolites, the number of metabolites that are retained could be doubled as compared to reversed-phase liquid chromatography alone. The presented work further demonstrates how the distinct selectivity of porous graphitized carbon complements reversed-phase liquid chromatography and extends the metabolome coverage of conventional LC-MS based methods in metabolomics to biologically important, but analytically challenging compound groups such as sugar phosphates. Both metabolic profiling and metabolic fingerprinting benefit from this method's increased separation capabilities that enhance sample throughput and the biological information content of LC-MS data. An inter-platform comparison with GC- and LC-tandem MS analyses confirmed the validity of the presented two-dimensional approach in the analysis of yeast cell extracts from P. pastoris.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25824707 PMCID: PMC4719141 DOI: 10.1039/c5an00206k
Source DB: PubMed Journal: Analyst ISSN: 0003-2654 Impact factor: 4.616
Fig. 1Setup for RP-PGC-ESI-MS. A two-position six-port valve is employed as switching valve to mediate the fraction transfer. The valve was set to position A for 0–2.5 min and position B between 2.5 and 20 min run time.
List of 82 metabolites used to assess the metabolome coverage of RP-PGC-TOFMS. 37 metabolites were retained on the RP column and 30 eluted near the void volume of the RP column and were hence automatically analyzed on the second-dimension PGC column. 15 metabolites were excluded from further analysis (“n.a.”). The repeatability precision of retention times was calculated from the observed retention times in repeated injections with a step-wise increase of the matrix load to an 8-fold amount. A cell extract sample from P. pastoris was analyzed in an inter-platform comparison of metabolite quantitation employing RP-PGC-TOFMS, RPLC-MS/MS and GC-MS/MS
|
| |||||||||||||
| Abbr. | Metabolite | Polarity | Exact mass, | RP | PGC | Retention time, min | Retention time RSD ( | RP-PGC-TOFMS | RPLC-MS/MS | GC-MS/MS | |||
| Average | SD | Average | SD | Average | SD | ||||||||
| AAA | α-Aminoadipic acid | + | 162.0761 | X | 5.0 | 0.1% | 1.5 | <0.1 | 1.5 | <0.1 | |||
| Aco |
| + | 172.0002 | n.a. | n.a. | n.a. | n.a. | ||||||
| Ade | Adenine | + | 136.0618 | X | 2.7 | 0.4% | <LOD | ||||||
| ADP | Adenosine diphosphate | – | 426.0221 | X | 2.7 | 0.1% | 6.9 | 1.6 | |||||
| AKG | α-Ketoglutarate | – | 145.0142 | X | 3.0 | 1.0% | 2.8 | 0.3 | |||||
| Ala | Alanine | + | 90.0550 | X | 4.2 | 0.3% | 2.2 | 0.1 | 53 | 1 | |||
| 3AMP | 3′-Adenosine monophosphate | – | 346.0558 | X | 4.7 | 0.2% | <LOD | <LOD | |||||
| 5AMP | 5′-Adenosine monophosphate | – | 346.0558 | X | 3.1 | 0.1% | 1.4 | 0.1 | 2.9 | 0.1 | |||
| Arg | Arginine | + | 175.1190 | X | 3.2 | 0.7% | 58 | 1 | |||||
| Asin | Adenosine | + | 268.1040 | X | 5.6 | 0.3% | <LOD | ||||||
| Asn | Asparagine | + | 133.0608 | X | 3.7 | 0.5% | 5.3 | 0.4 | 5.2 | 0.1 | |||
| Asp | Aspartate | + | 134.0448 | X | 4.2 | 0.4% | 12 | <1 | 8.5 | 0.5 | |||
| ATP | ATP | + | 508.0030 | n.a. | n.a. | n.a. | n.a. | ||||||
| Cit | Citrate | – | 191.0197 | X | 3.6 | 0.4% | 10 | <1 | 9.8 | 0.1 | |||
| 5CMP | 5′-Cytidine monophosphate | – | 322.0446 | n.a. | n.a. | n.a. | n.a. | ||||||
| Cys | Cysteine | + | 122.0270 | n.a. | n.a. | n.a. | n.a. | ||||||
| Cys-Gly | Cysteinylglycine | + | 179.0485 | n.a. | n.a. | n.a. | n.a. | ||||||
| Cysta | Cystathionine | + | 223.0747 | X | 3.8 | 0.4% | 2.6 | 0.1 | <LOD | ||||
| Cyt | Cytosine | + | 112.0505 | n.a. | n.a. | n.a. | n.a. | ||||||
| DHAP | Dihydroxyacetonephosphate | – | 168.9907 | n.a. | n.a. | n.a. | n.a. | ||||||
| DHIV | Dihydroxyisovalerate | – | 133.0506 | n.a. | n.a. | n.a. | n.a. | ||||||
| E4P | Erythrose 4-phosphate | – | 199.0013 | X | 11.9 | 0.7% | 1.7 | 0.1 | |||||
| F6P | Fructose 6-phosphate | – | 259.0224 | X | 11.6 | 0.2% | 1.6 | 0.1 | 1.3 | <0.1 | |||
| FAD | Flavinadenine dinucleotide | + | 786.1644 | X | 7.1 | 0.0% | 0.1 | <0.1 | |||||
| Fum | Fumarate | – | 115.0037 | X | 9.7 | 0.4% | 2.4 | 0.1 | 4.0 | 0.1 | 3.4 | 0.1 | |
| G6P | Glucose 6-phosphate | – | 259.0224 | X | 11.8 | 0.3% | 7.2 | 0.2 | 6.6 | <0.1 | |||
| GDP | Guanosine diphosphate | – | 442.0171 | X | 9.3 | 1.1% | <LOD | ||||||
| Glc-On | Gluconate | – | 195.0510 | X | 6.0 | 0.7% | 0.016 | 0.001 | |||||
| Gln | Glutamine | + | 147.0764 | X | 3.9 | 0.3% | 94 | 1 | 88 | <1 | |||
| Glu | Glutamate | + | 148.0604 | X | 4.3 | 0.9% | |||||||
| Glu-Cys | Glutamylcysteine | + | 251.0696 | n.a. | n.a. | n.a. | n.a. | ||||||
| Gly | Glycine | + | 76.0393 | n.a. | n.a. | n.a. | n.a. | ||||||
| GMP | 5′-Guanosine monophosphate | – | 362.0507 | X | 3.6 | 0.4% | 0.2 | <0.1 | 0.21 | <0.01 | |||
| Gnin | Guanine | + | 152.0567 | X | 2.9 | 0.4% | <LOD | ||||||
| GSH | Glutathione, reduced | + | 308.0911 | X | 3.2 | 0.2% | 8.0 | 0.4 | |||||
| Gsin | Guanosine | + | 284.0989 | X | 5.6 | 0.5% | <LOD | ||||||
| GSSG | Glutathione, oxidized | + | 613.1592 | X | 5.3 | 0.4% | 8.1 | 0.2 | |||||
| Hcys | Homocysteine | + | 136.0427 | n.a. | n.a. | n.a. | n.a. | ||||||
| His | Histidine | + | 156.0768 | X | 3.2 | 1.1% | 5.4 | 0.2 | |||||
| H-Ser | Homoserine | + | 120.0655 | X | 3.7 | 0.6% | |||||||
| I-Cit | Isocitrate | – | 191.0197 | X | 2.6 | 0.4% | 0.10 | 0.02 | 0.13 | <0.01 | 0.08 | <0.01 | |
| Ile | Isoleucine | + | 132.1019 | X | 4.4 | 0.3% | 0.036 | 0.010 | 0.49 | 0.01 | |||
| Kile | Ketoisoleucine | – | 129.0557 | X | 8.3 | 0.2% | 0.038 | 0.009 | |||||
| K-Val | Ketoisovalerate | + | 117.0546 | X | 6.6 | 0.6% | <LOD | <LOD | |||||
| Lac | Lactate | – | 89.0244 | n.a. | n.a. | n.a. | n.a. | ||||||
| Leu | Leucine | + | 132.1019 | X | 4.8 | 0.3% | 0.39 | 0.06 | 0.39 | 0.02 | 0.29 | 0.03 | |
| Lys | Lysine | + | 147.1128 | X | 2.7 | 0.6% | 8.2 | 0.7 | 9.5 | 0.5 | |||
| M6P | Mannose 6-phosphate | – | 259.0224 | X | 12.4 | 0.2% | 3.4 | 0.1 | 2.9 | <0.1 | |||
| Mali | Malate | – | 133.0142 | X | 9.7 | 0.3% | 18 | <1 | 16 | <1 | 17 | <1 | |
| Man-Ol | Mannitol | + | 183.0863 | X | 4.4 | 0.6% | 0.67 | 0.15 | |||||
| Met | Methionine | + | 150.0583 | X | 3.0 | 0.3% | 0.38 | 0.10 | 0.48 | 0.04 | |||
| Mt1P | Mannitol 1-phosphate | – | 261.0381 | X | 11.0 | 0.2% | <LOD | <LOD | |||||
| NAD+ | Nicotinamide adenine dinucleotide, oxidized | + | 664.1164 | X | 4.1 | 0.4% | 2.9 | 0.1 | |||||
| NADH | Nicotinamide adenine dinucleotide, reduced | – | 664.1175 | X | 5.6 | 0.7% | 9.2 | 0.2 | |||||
| NADP+ | Nicotinamide adenine dinucleotide phosphate, oxidized | + | 744.0827 | X | 3.3 | 0.4% | 0.41 | 0.03 | |||||
| NADPH | Nicotinamide adenine dinucleotide phosphate, reduced | – | 744.0838 | X | 5.6 | 0.5% |
| ||||||
| Oac | Oxaloacetic acid | – | 130.9986 | n.a. | n.a. | n.a. | n.a. | ||||||
| OAS |
| + | 148.0604 | X | 4.3 | 0.9% | |||||||
| PEP | Phosphoenolpyruvate | – | 165.9673 | n.a. | n.a. | n.a. | n.a. | ||||||
| 2PG | 2-Phosphoglycerate | – | 184.9857 | X | 11.5 | 0.3% | 0.083 | 0.005 | <LOD | ||||
| 3PG | 3-Phosphoglycerate | – | 184.9857 | X | 11.9 | 0.2% | 0.75 | 0.03 | 0.51 | 0.03 | |||
| 6PGA | 6-Phosphogluconate | – | 275.0174 | X | 14.0 | 0.1% | 0.41 | 0.01 | 0.28 | 0.05 | |||
| Phe | Phenylalanine | + | 166.0863 | X | 6.1 | 0.8% | 0.34 | 0.01 | 0.40 | 0.01 | 0.42 | 0.02 | |
| Pro | Proline | + | 116.0706 | X | 4.1 | 0.2% | <LOD | 11 | <1 | ||||
| Pyr | Pyruvate | – | 87.0088 | X | 2.6 | 0.3% | 0.97 | 0.06 | |||||
| R5P | Ribose 5-phosphate | – | 229.0119 | X | 11.2 | 0.5% | 0.66 | 0.03 | 1.8 | <0.1 | |||
| Ri-Fl | Riboflavin | + | 377.1456 | X | 7.6 | 0.1% | <LOD | <LOD | |||||
| Rl5P | Ribulose 5-phosphate | – | 229.0119 | X | 11.7 | 0.2% | 0.34 | 0.04 | |||||
| S7P | Sedoheptulose 7-phosphate | – | 289.0330 | X | 12.2 | 0.3% | 2.6 | 0.2 | 2.7 | 0.1 | |||
| SAH |
| + | 385.1289 | X | 5.5 | 0.4% | 0.089 | 0.019 | |||||
| SAM |
| + | 399.1451 | X | 4.2 | 0.8% | <LOD | ||||||
| Ser | Serine | + | 106.0499 | X | 3.5 | 0.6% | 4.8 | 1.9 | 4.2 | 0.2 | |||
| Suc | Succinate | – | 117.0193 | X | 4.6 | 0.6% | 1.9 | 0.1 | 2.0 | 0.1 | 1.6 | 0.1 | |
| Thi | Thiamine | + | 265.1118 | n.a. | n.a. | n.a. | n.a. | ||||||
| Thr | Threonine | + | 120.0655 | X | 3.7 | 0.6% | |||||||
| Thy | Thymine | + | 127.0502 | X | 5.7 | 0.7% | <LOD | ||||||
| Trp | Tryptophan | + | 205.0972 | X | 6.7 | 0.2% | 0.093 | 0.006 | 0.077 | 0.001 | |||
| Tyr | Tyrosine | + | 182.0812 | X | 4.6 | 0.4% | 0.41 | 0.03 | 0.53 | <0.01 | 0.46 | 0.07 | |
| 5UMP | 5′-Uridine monophosphate | – | 323.0286 | X | 3.0 | 0.3% | 0.54 | 0.11 | 0.26 | 0.03 | |||
| Ura | Uracil | + | 113.0346 | X | 3.1 | 0.4% | <LOD | ||||||
| Uri | Uridine | + | 245.0768 | X | 5.0 | 0.1% | <LOD | ||||||
| Val | Valine | + | 118.0863 | X | 4.7 | 0.6% | 2.6 | 0.2 | 2.2 | 0.1 | |||
Poor linear calibration due to strong interaction with stationary phase at low concentrations.
Glutamic acid and ortho-acetyl serine co-elute.
The reliable determination of intracellular NAD+, NADH, NADP+, NADPH, GSH and GSSG levels requires dedicated sample preparation methods.[45,46] The validated RPLC-MS/MS methodology including sample preparation does not include these metabolites, therefore reference values are not available.
Homoserine and threonine co-elute.
Fig. 2Assessment of peak widths using RP and PGC separately or coupled (RP-PGC), shown exemplarily for malic acid (A) and serine (B). Peak widths are given as full peak width at half-maximal peak height (FWHM). The RP chromatogram shows the peak that is loaded onto the PGC column, while the comparison between PGC and RP-PGC peak widths shows that modulation does not introduce peak broadening.